Drug Profile
RLS RX1
Alternative Names: RLS-RX1Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator PharmaLogika
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Restless legs syndrome
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Restless legs syndrome in USA (unspecified route) (PharmaLogika website, August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Restless legs syndrome in USA